United Therapeutics (UTHR) EBT Margin (2009 - 2026)

United Therapeutics has disclosed EBT Margin across 18 years of filings, most recently posting 47.58% for Q2 2026.

• In Q2 2026, EBT Margin fell 356.0% year-over-year to 47.58%; the TTM figure through Jun 2026 stood at 49.87% (down 267.0% YoY), while the FY2025 annual figure was 53.85%, up 36.0% from the prior year.
• EBT Margin came in at 47.58% for Q2 2026 at United Therapeutics, up from 40.73% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 66.83% in Q1 2022 to a low of 32.26% in Q2 2022.
• Average EBT Margin over 5 years is 51.87%, with a median of 53.6% recorded in 2024.
• The largest YoY upside for EBT Margin was 5826 bps in 2022 against a maximum downside of 1623 bps in 2022.
• Over 5 years, EBT Margin stood at 36.38% in 2022, then surged by 32 bps to 48.06% in 2023, then gained by 12 bps to 53.88% in 2024, then increased by 4 bps to 56.19% in 2025, then decreased by 15 bps to 47.58% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 47.58% in Q2 2026, 40.73% in Q1 2026, and 56.19% in Q4 2025.